Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

RealiseD Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases

Coordinator
Sigmund Freud Privatuniversitat Wien GmbH, Austria
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€8.5m
Total cost
€17.2m
Partners
53 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101165912

What the project is doing

In the project's own words, from its summary on CORDIS.

RealiseD implements a collaborative and compRehensive mEthodological and operational Approach to cLinical trIalS in rarE Diseases enabling timely drug development and approval centred on patients’ needs with high level of evidence reachable in a limited environment. The core of RealiseD operational approaches includes the systematic procedures for patients’ referral, the certification of clinical sites and filling the gaps for successful development of rare and ultra rare diseases[(U)RD]’ clinical trials using 4 (U)RD diseases from 4 European Research Networks (ERNs).

RealiseD methodological teams will optimise innovative statistical and quantitative approaches for design and analysis of (U)RD-CTs developed in the past 10 years and refined in the last years to facilitate the regulatory pathway for innovative drug development. RealiseD is implemented in a public private partnership consortium including regulators and HTA bodies representatives to co-create operational and methodological approaches in an iterative procedure using a multistakeholders’ agreement process.

RealiseD will increase the incentives and motivation for the pharmaceutical industry by reducing many uncertainties on the path of drug development in (U)RD that will follow widely accepted rules. To achieve these innovative approaches, RealiseD will capitalise on an international multistakeholders effort as the problem in (U)RD drug development cannot be solved in a restricted geographical area. With the development and deployment of playbooks arising from the co-created developments, RealiseD will ascertain visibility and readiness of the innovations.

The overall ambition of RealiseD is to change the paradigm of CT design for U(RD) by enlarging the spectrum of methodological and operational approaches and to establish a sustainable, innovative, and optimised CT paradigm for U(RD) medicinal product development programs, while maximizing the acceptance by all stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Sigmund Freud Privatuniversitat Wien GmbHWienAustriaCoordinator
Genzyme Argentinia S.A.MartinezARAssociatedpartner
Medizinische Universitaet WienWienAustriaParticipant
Paris-Lodron-Universitat SalzburgSalzburgAustriaParticipant
International Drug Development Institute SAOttignies-Louvain-La-NeuveBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Sanofi-Aventis Belgium SADiegemBelgiumAssociatedpartner
Ucb BiopharmaBruxelles / BrusselBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Universiteit HasseltHasseltBelgiumParticipant
Bayer Consumer Care AGBaselSwitzerlandAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Boehringer Ingelheim Pharma GmbH &co KgIngelheimGermanyAssociatedpartner
Otto-Von-Guericke-Universitaet MagdeburgMagdeburgGermanyParticipant
Ruhr-Universitaet BochumBochumGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Stiftung Fur Qualitat Und Wirtschaftlichkeit Im GesundheitswesenBerlinGermanyParticipant
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen RechtsGoettingenGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Fundacio Privada per a La Recerca I La Docencia Sant Joan De DeuEsplugues De LlobregatSpainThird party
Hospital Sant Joan De DeuEsplugues De LlobregatSpainParticipant
Sanofi Aventis SABarcelonaSpainAssociatedpartner
Teamit Research S.l.BarcelonaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Eurordis - Rare Diseases EuropeParisFranceParticipant
Hopitaux Universitaires De StrasbourgStrasbourg CedexFranceParticipant
Institut De Recherches Internationales ServierGif-Sur-YvetteFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Ipsen Innovation SASParisFranceParticipant
Sanofi Winthrop IndustrieGentillyFranceAssociatedpartner
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Azienda Sanitaria Universitaria Friuli CentraleUdineItalyParticipant
Istituto Ortopedico RizzoliBolognaItalyParticipant
Sanofi SrlMilanoItalyAssociatedpartner
Universita HumanitasPieve EmanueleItalyParticipant
Conect4children StichtingUtrechtNetherlandsParticipant
Critical Path Institute StichtingAmsterdamNetherlandsParticipant
Eatris EricAmsterdamNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
The European Medicines AgencyAmsterdamNetherlandsParticipant
Universitetet I OsloOsloNorwayThird party
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
Bayer Public Limited CompanyNewburyUnited KingdomAssociatedpartner
Alexion Pharmaceuticals IncBostonUnited StatesAssociatedpartner
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner
Sanofi GenzymeCambridgeUnited StatesAssociatedpartner
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner
Servier BIO-INNOVATION LLCBostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI